Erratum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases (Scientific Reports (2015) 5:11827 DOI: 10.1038/srep11827);Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Basarab, Gregory S ^a   Kern, Gunther H ^b   McNulty, John ^c   Mueller, John P ^d   Lawrence, Kenneth ^d   Vishwanathan, Karthick ^b   Alm, Richard A ^b   Barvian, Kevin ^e   Doig, Peter ^b   Galullo, Vincent ^b   Gardner, Humphrey ^b   Gowravaram, Madhusudhan ^f   Huband, Michael ^g   Kimzey, Amy ^b   Morningstar, Marshall ^h   Kutschke, Amy ^b   Lahiri, Sushmita D ^b   Perros, Manos ^c   Singh, Renu ^a   Schuck, Virna J A ⁱ   Tommasi, Ruben ^c   Walkup, Grant ^b   Newman, Joseph V ^b   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ASTRAZENECA   (United Kingdom)

^c Shire Pharmaceuticals   (United States)

^d Entasis Therapeutics   (United States)

^e ALBANY MOLECULAR RESEARCH INC   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g JMI LABORATORIES   (United States)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ Norvartis Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; QUINOLONE DERIVATIVE; SPIRO COMPOUND; ZOLIFLODACIN;

ADULT; ANIMAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; CLINICAL TRIAL; CONFORMATION; DISEASE MODEL; DOG; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; GONORRHEA; HAPLORHINI; HUMAN; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MOLECULAR MODEL; MOUSE; MUTATION; NEISSERIA GONORRHOEAE; PHASE 1 CLINICAL TRIAL; RAT; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; BARBITURATES; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE II; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GONORRHEA; HAPLORHINI; HUMANS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEISSERIA GONORRHOEAE; RATS; SPIRO COMPOUNDS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TOPOISOMERASE II INHIBITORS; YOUNG ADULT;

EID: 84937047439     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14157     Document Type: Erratum

References (65)

1. Rodvolk, K. A. , McConeghy, K. W. Methicillin-resistant Staphylococcus aureus therapy: past, present and future. Clin. Infect. Dis. 58, S20-S27 (2014).
2. Unemo, M., Golparian, D. , Shafer, W. M. Challenges with gonorrhea in the era of multi-drug and extensively drug resistance-are we on the right track? Expert Rev. Anti Infect. Ther. 12, 653-656 (2014).
3. Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009).
4. Ruble, J. C. et al. Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates. J. Am. Chem. Soc. 131, 3991-3997 (2009).
5. Basarab, G. S. et al. Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold-SAR and in vivo characterization. J. Med. Chem. 57, 9078-9095 (2014).
6. Basarab, G. S. et al. Synthesis of a tetrahydronaphthyridine spiropyrimidinetrione DNA gyrase inhibiting antibacterial agent-differential substitution at all five carbon atoms of pyridine. Org. Lett. 16, 6456-6459 (2014).
7. Huband, M. D. et al. In vitro antibacterial activity of AZD0914: a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob. Agents and Chemother. 59, 467-474 (2015).
8. Jacobsson, S. et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrugresistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob. Agents Chemother. 58, 5585-5588 (2014).
9. Alm, R. A. et al. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of crossresistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 59, 1478-1486 (2015).
10. Spellberg, B. , Shlaes, D. Prioritized current unmet needs for antibacterial therapies. Clin. Pharmacol. Ther. 96, 151-153 (2014).
11. CDC Fact Sheet, Gonorrhea Treatment Guidelines. (2013) Available at: http://www.cdc.gov/nchhstp/newsroom/docs/Gonorrhea-Treatment-Guidelines-FactSheet.pdf. (Accessed: 28 April 2015).
12. Unemo, M. , Shafer, W. M. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann. N. Y. Acad. Sci. 1230, E19-E28 (2011).
13. Morita-Ishihara, T. et al. Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae. J. Antimicrob. Chemother. 69, 2086-2090 (2014).
14. Tapsall, J. et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58, 683-687 (2009).
15. Bolan, G. A., Sparling, P. F. , Wasserheit, J. N. The emerging threat of untreatable gonococcal infection. N. Engl. J. Med. 366, 485-487 (2012).
16. Ince, D. , Hooper, D. C. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents and Chemother. 45, 2755-2764 (2001).
17. Kirkcaldy, R. D., Kidd, S., Weinstock, H. S., Papp, J. R. , Bolan, G. A. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sexually Transmitted Infections 89, iv5-iv10 (2013).
18. Black, M. T. et al. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob. Agents Chemother. 52, 3339-3349 (2008).
19. Ross, J. E., Scangarella-Oman, N. E., Flamm, R. K. , Jones, R. N. Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J. Clin. Microbiol. 52, 2629-2632 (2014).
20. Reck, F. et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: antibacterial agents with an improved safety profile. J. Med. Chem. 55, 6916-6933 (2012).
21. Bisacchi, G. S. , Manchester, J. I. A new-class antibacterial-almost. Lessons in drug discovery and development: a critical analysis of > 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV. ACS Infect. Dis. 1, 4-41 (2015).
22. Mayer, C. , Janin, Y. L. Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem. Rev. 114, 2313-2342 (2014).
23. Federal Register, Determination That ALBAMYCIN (Novobiocin Sodium) Capsule, 250 Milligrams, Was Withdrawn From Sale for Reasons of Safety or Effectiveness. (2011) Available at: https://www.federalregister.gov/articles/2011/01/19/2011-1000/determination-that-albamycin-novobiocin-sodium-capsule-250-milligrams-was-withdrawn-from-sale-for. (Accessed: 28 April 2015).
24. Barvian, K., Basarab, G. S., Gowravaram, M. R., Hauck, S. I. , Zhou, F. Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections. USP 8, 658, 641 (2014).
25. Basarab, G. S., Gowravaram, M. R., Hauck, S. I. , Zhou, F. Compounds and methods for treating bacterial infections. United States Patent 8, 889, 671 (2014).
26. European Medicines Agency, Pre-authorisation Evaluation of Medicines for Human Use. (2009), Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500060988.pdf. (Accessed: 28 April 2015).
27. Harwood, P. J. , Giannoudis, P. V. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms Expert Opinion in Drug Safety 3, 405-414 (2002).
28. Doherty, A. T. et al. Bone marrow micronucleus frequencies in the rat after oral administration of cyclophosphamide, hexamethylphosphoramide or gemifloxacin for 2 and 28 days Toxicol. Res. 2, 321-327 (2013).
29. Lovering, F., Bikker, J. , Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756 (2009).
30. Attassi, K., Hershberger, E., Alam, R. , Zervos, M. J. Thrombocytopenia associated with linezolid therapy Clin. Infect. Dis. 34, 695-698 (2002).
31. Cheah, C. Y., De Keulenaer, B. , Leahy, M. F. Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern. Med. J. 39, 619-623 (2009).
32. Sousa, J., Alves, G., Fortuna, A. , Falcao, A. Third and fourth generation fluoroquinolone antibacterials: A systematic review of safety and toxicity profiles. Curr. Drug Safety 9, 89-105 (2014).
33. Falagas, M. E., Rafailidis, P. I. , Rosmarakis, E. S. Arrhythmias associated with fluoroquinolone therapy. Int. J. Antimicrob. Agents 29, 374-379 (2007).
34. Katritsis, D. , Camm, A. J. Quinolones: Cardioprotective or cardiotoxic? PACE 26, 2317-2320 (2003).
35. Aldred, K. J., Kerns, R. J. , Osheroff, N. Mechanism of quinolone action and resistance. Biochemistry 53, 1565-1574 (2014).
36. Champoux, J. J. DNA topisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413 (2001).
37. Aldred, K. J., McPherson, S. A., Turnbough, C. L., Kerns, R. J. , Osheroff, N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 41, 4628-4639 (2013).
38. Pan, X. S., Dias, M., Palumbo, M. , Fisher, L. M. Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage. Nucleic Acids Res. 36, 5516-5529 (2008).
39. Drlica, K. et al. Bypassing fluoroquinolone resistance with quinazolinediones: Studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem. Biol. 9, 2895-2904 (2014).
40. Miller, A. A. et al. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob. Agents Chemother. 52, 2806-2812 (2008).
41. Basarab, G. S. et al. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents. J. Med. Chem. 56, 8712-8735 (2013).
42. Ruiz, J. et al. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. J. Antimicrob. Chemother. 48, 545-548 (2001).
43. Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. , Nakamura, S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35, 1647-1650 (1991).
44. Balani, S. K. et al. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab. Dispos. 32, 1092-1095 (2004).
45. Craig, W. A. , Dalhoff, A. in Handbook of experimental pharmacology (eds Kuhlman, J., Dalhoff, A. , Zeiller, H. J) 208-232 (Springer-Verlag, Berlin, Germany, 1998).
46. Andes, D. , Craig, W. A. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46, 1665-1670 (2002).
47. Jerse, A. E. et al. Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front. Microbiol. 2, 1-13 (2011).
48. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-10 (1998).
49. Leggett, J. E. et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thighinfection models. J. Infect. Dis. 159, 281-292 (1989).
50. Forrest, A. et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073-1081 (1993).
51. Kam, K. M., Lo, K. K., Lai, C., Lee, Y. S. , Chan, C. B. Ofloxacin susceptibilities of 5, 667 Neisseria gonorrhoeae strains isolated in Hong Kong. Antimicrob. Agents Chemother. 37, 2007-2008 (1997).
52. Diekema, D. J. , Jones, R. N. Oxazolidinones Drugs 59, 7-16 (2000).
53. Cunha, B. A. Antimicrobial therapy of multidrug-resistant S. pneumoniae, vancomycin-resistant Enterococci, and methicillinresistant S. aureus. Med. Clin. N. Am. 90, 1165-1182 (2006).
54. Andes, D., van Ogtrop, M. L., Peng, J. , Craig, W. A. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46, 3484-3489 (2002).
55. Craig, W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22, 89-96 (1995).
56. Van Bambeke, F., Michot, J.-M., Van Eldere, J. , Tulkens, P. M. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11, 256-280 (2005).
57. Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C. , Schentag, J. J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42, 1411-1423 (2003).
58. Croom, K. F. , Goa, K. L. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63, 2769-2802 (2003).
59. B. Braun Medical Inc., Ceftriaxone for Injection and Dextrose Injection (2012) Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/050796orig1s011lbledt.pdf. (Accessed: 8th March 2015).
60. Popick, A. C. et al. Plasma protein binding of ceftriaxone. Xenobiotica. 17, 1139-1145 (1987).
61. Shapiro, A. B. , Andrews, B. Allosteric inhibition of the DNA-dependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors. Biochem. Pharmacol. 84, 900-904 (2012).
62. de Jonge, B. L. M., Kutschke, A., Uria-Nickelsen, M., Kamp, H. D. , Mills, S. D. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI). Antimicrob. Agents Chemother. 53, 3331-3336 (2009).
63. Blaser, J., Stone, B. B., Groner, M. C. , Zinner, S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentrations to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31, 1054-1060 (1987).
64. Tam, V. H. et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone. J. Infect. Dis. 195, 1818-1827 (2007).
65. ClinicalTrials.gov, A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914. (2014) Available at: https://clinicaltrials.gov/ct2/show/NCT01929629?term= AZD0914&rank=2. (Accessed: 8th March 2015).